## TRADEMARK ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Notice of Grant of Security Interest

#### **CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
Bioglan Pharmaceuticals Corp.		11/14/2005	CORPORATION: DELAWARE

### RECEIVING PARTY DATA

Name:	Wachovia Bank, National Association, as Administrative Agent
Street Address:	201 S. College Street
Internal Address:	CP-8
City:	Charlotte
State/Country:	NORTH CAROLINA
Postal Code:	28288
Entity Type:	national banking association: UNITED STATES

PROPERTY NUMBERS Total: 17

Property Type	Number	Word Mark
Registration Number:	2893077	ZONALON
Registration Number:	2725852	ADOXA
Registration Number:	2843401	SOLARAZE
Registration Number:	2399228	A-FIL
Registration Number:	2239725	DELIVERING SERIOUS MEDICINE FOR DERMATOLOGY
Registration Number:	2293247	BIOGLAN PHARMA
Registration Number:	2137236	BETA-LIFTX
Registration Number:	2125549	LIFTX
Registration Number:	2442940	TXSYSTEMS
Registration Number:	2197069	AFIRM
Registration Number:	1612636	BENZASHAVE
Registration Number:	2183172	BIOGLAN
Registration Number:	1391339	PRAMEGEL

TRADEMARK "REEL: 003219 FRAME: 0342

900038886

Registration Number:	1436153	BM BIOGLAN MICELLIZED
Serial Number:	78398969	ADOXA DOXYCYCLINE TABLETS SMALL. EASY TO SWALLOW.
Serial Number:	78136606	BIOGLAN PHARMACEUTICALS
Serial Number:	76099139	BIOGLAN BIOGLAN PHARMA, INC.

#### **CORRESPONDENCE DATA**

Fax Number: (919)416-8339

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 919 286-8049

Email: PTO\_TMconfirmation@mvalaw.com

Correspondent Name: Moore & Van Allen PLLC

Address Line 1: 430 Davis Drive

Address Line 2: Suite 500

Address Line 4: Morrisville, NORTH CAROLINA 27560

ATTORNEY DOCKET NUMBER:	512485.5014NTBIOGLANJES
NAME OF SUBMITTER:	John E. Slaughter
Signature:	/John E. Slaughter/
Date:	01/03/2006

#### Total Attachments: 4

source=NGSI-T2 Bioglan Pharmaceuticals#page1.tif source=NGSI-T2 Bioglan Pharmaceuticals#page2.tif source=NGSI-T2 Bioglan Pharmaceuticals#page3.tif source=NGSI-T2 Bioglan Pharmaceuticals#page4.tif

#### NOTICE

OF

#### GRANT OF SECURITY INTEREST

IN

#### **TRADEMARKS**

United States Patent and Trademark Office

Gentlemen:

Please be advised that pursuant to the Amended and Restated Security Agreement dated as of November 14, 2005 (as the same may be amended, modified, extended or restated from time to time, the "Security Agreement") by and among the Obligors party thereto (each an "Obligor" and collectively, the "Obligors") and Wachovia Bank, National Association, as Administrative Agent (the "Administrative Agent") for the lenders referenced therein (the "Lenders"), the undersigned Obligor has granted a continuing security interest in and continuing lien upon, the trademarks and trademark applications shown below to the Administrative Agent for the ratable benefit of the Lenders:

#### **TRADEMARKS**

Description of

Trademark No.

Trademark

Date of Trademark

See Schedule 1

#### TRADEMARK APPLICATIONS

Description of Trademark

Trademark Application No.

Applied For

Date of Trademark **Application** 

See Schedule 1

CHAR1\833864v1

The Obligors and the Administrative Agent, on behalf of the Lenders, hereby acknowledge and agree that the security interest in the foregoing trademarks and trademark applications (i) may only be terminated in accordance with the terms of the Security Agreement and (ii) is not to be construed as an assignment of any trademark or trademark application.

The Obligors and the Administrative Agent, on behalf of the Lenders, hereby acknowledge and agree that the security interest in the foregoing trademarks and trademark applications (i) may only be terminated in accordance with the terms of the Security Agreement and (ii) is not to be construed as an assignment of any trademark or trademark application.

Very truly yours,

BIOGLAN PHARMACEUTICALS CORP., a Delaware corporation

Ву:	 	
Name:		
Title:	-	

Acknowledged and Accepted:

WACHOVIA BANK, NATIONAL ASSOCIATION,

as Administrative Agent

By: Scott Santa Cruz

Title: Director

## Schedule 1

# **Bioglan Pharmaceuticals Corp.** (Delaware Corporation)

## **U.S.** Trademarks

## **Registered Marks**

Mark	Registration No.	Registration Date
ZONALON	2893077	10/12/04
ADOXA	2725852	06/10/03
SOLARAZE	2843401	05/18/04
A-FIL	2399228	10/31/00
DELIVERING SERIOUS MEDICINE FOR DERMATOLOGY	2239725	04/13/99
BIOGLAN PHARMA and Design	2293247	11/16/99
BETA-LIFTX	2137236	02/17/98
LIFTX <beta> and Design</beta>	2125549	12/30/97
TXSYSTEMS	2442940	04/10/01
AFIRM	2197069	10/20/98
BENZASHAVE	1612636	09/11/90
BIOGLAN	2183172	08/25/98
PRAMEGEL	1391339	04/29/86
BM BIOGLAN MICELLIZED and Design	1436153	04/14/87

## **Pending Applications**

Mark	Application No.	Filing Date
ADOXA DOXYCYCLINE TABLETS SMALL.	78398969	04/08/04
EASY TO SWALLOW. BIOGLAN PHARMACEUTICALS and Design	78136606	06/18/02
BIOGLAN BIOGLAN PHARMA, INC. and Design	76099139	07/28/00

CHAR1\833864v1

**RECORDED: 01/03/2006**